Omeros Corporation
OMEROmeros Corporation is an American biopharmaceutical company focused on the discovery, development, and commercialization of drugs for areas such as inflammation, respiratory illness, and Central Nervous System disorders. It leverages its proprietary small-molecule and biologic platforms to develop therapies aimed at underserved medical needs.
Company News
The Portnoy Law Firm has initiated an investigation into possible securities fraud at Omeros Corporation following the European Medicines Agency's negative opinion on the company's narsoplimab marketing authorization application on June 26, 2026. The negative regulatory decision triggered a 19.12% stock price decline, dropping from $10.72 to $8.6...
Heartflow, an AI-driven diagnostic platform, shows strong 40% revenue growth but faces reimbursement headwinds and remains unprofitable. Omeros is transitioning to commercial stage with its newly approved drug Yartemlea, posting early Q1 2026 revenue of $9.89 million. The article recommends Omeros as the safer bet for 2026 despite trading at a pr...
The article compares two emerging biotech stocks: Intellia Therapeutics, which focuses on CRISPR gene-editing technology with promising Phase III trial data but significant losses and clinical risks, and Omeros, which recently achieved FDA approval for Yartemlea and posted its first commercial revenue of $9.89 million. While Intellia offers highe...
Sagimet Biosciences appointed Dr. Andreas Grauer as Chief Medical Officer effective April 20, 2026, replacing retiring Dr. Eduardo Martins who will serve as external scientific advisor. Grauer brings over two decades of biopharmaceutical leadership experience from roles at Omeros, Federation Bio, Corcept Therapeutics, and Amgen. He received an in...
Omeros stock surged nearly 76% after receiving FDA approval for Yartemlea, a treatment for TA-TMA (hematopoietic stem cell transplant-associated thrombotic microangiopathy), a potentially fatal complication from stem cell transplants. This is the first and only FDA-approved treatment for this indication. The company plans to launch the drug in Ja...
